吃绥美凯要注意什么

Trimicay (dolutegravir) is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. Trivicay is based on a treatment regimen of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014. Today we will learn more about what to pay attention to when eating Suimeikai?

The recommended dosage of Suimeike (Dolutea Abalamib Tablets) is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

Missed dose: If the patient misses a dose of Suimeikan (Domitabalamid Tablets) and there are more than 4 hours before the next dose, Suimeike should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

Geriatric patients: There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged 65 years and older, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering Trimax in this age group.

Renal damage: Patients with creatinine clearance less than 50 mL/min are not recommended to take Suimeikai (Doteta abalamide tablets). 

Hepatic Impairment Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of Trimax (doluteabalamide) is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6): Close monitoring is required, including monitoring of abacavir plasma levels if feasible.

Pediatric Population: The safety and effectiveness of Suimeike (dolute abalamib tablets) in children under 12 years of age have not been established. No data yet.

Method of administration: Oral administration. Trimax may be taken with or without food.

The above is what you should pay attention to when taking Suimeikai (Doteta abalami tablets). I hope it can help you!